← Leaderboards
Joel M Gelfand
University Of Pennsylvania
$10,446,570
Attributed
$10,644,194
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–17$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$10,248,946 · 6
FDA$395,248 · 1
By mechanism
R01$7,980,562 · 3
RC1$1,000,000 · 1
K24$869,576 · 1
K23$662,310 · 1
F32$131,746 · 1
Top collaborators
- Alain H Rook2 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Hank F Kung$16,346,808
- Nalaka S Gooneratne$12,307,702
- Lewis A Chodosh$38,386,361
- Sean P Hennessy$26,496,214
- Sharon Meropol$749,605
Others in their field
Top investigators on “Psoriasis”
- James Tilford Elder · University Of Michigan At Ann Arbor$26,149,187
- Eugene W. St Clair · Duke University$24,182,181
- Nicole Leanne Ward · Vanderbilt University Medical Center$12,593,847
- George L Sen · University Of California, San Diego$10,424,121
- Paul A Khavari · Stanford University$10,048,310
- Pierre Coulombe · Johns Hopkins University$9,906,781
Research focus
PsoriasisBaseRisk FactorsAffectInnovationInflammatoryCardiovascular DiseasesSkinPathway InteractionsEventResearch PersonnelMyocardial InfarctionStrokeCessation Of LifeAtherosclerosisInflammationCardiovascular Risk FactorCardiovascular SystemBody Surface AreaMediatingChronicFutureCross-Sectional StudiesAmerican
Grant awards (27)
A trial to determine the effect of psoriasis treatment on cardiometabolic disease$763,099
R01 · FY2017 · HL · contact PI
Psoriasis and the Risk of Diabetes$181,293
K24 · FY2017 · AR · contact PI
A trial to determine the effect of psoriasis treatment on cardiometabolic disease$767,538
R01 · FY2016 · HL · contact PI
Psoriasis and the risk of diabetes$181,253
K24 · FY2016 · AR · contact PI
A trial to determine the effect of psoriasis treatment on cardiometabolic disease$737,686
R01 · FY2015 · HL · contact PI
Psoriasis and the risk of diabetes$181,889
K24 · FY2015 · AR · contact PI
Psoriasis and the risk of diabetes$162,667
K24 · FY2014 · AR · contact PI
A trial to determine the effect of psoriasis treatment on cardiometabolic disease$718,499
R01 · FY2013 · HL · contact PI
The Risk of Myocardial Infarction in Patients with Psoriasis$648,965
R01 · FY2013 · HL · contact PI
Phase 1 Study of Resiquimod Gel Therapy for Cutaneous T-Cell Lymphoma$196,942
R01 · FY2013 · FD
Psoriasis and the risk of diabetes$162,474
K24 · FY2013 · AR · contact PI
A trial to determine the effect of psoriasis treatment on cardiometabolic disease$785,162
R01 · FY2012 · HL · contact PI
The Risk of Myocardial Infarction in Patients with Psoriasis$762,637
R01 · FY2012 · HL · contact PI
Phase 1 Study of Resiquimod Gel Therapy for Cutaneous T-Cell Lymphoma$198,306
R01 · FY2012 · FD
The Risk of Myocardial Infarction in Patients with Psoriasis$776,528
R01 · FY2011 · HL · contact PI
The Risk of Myocardial Infarction in Patients with Psoriasis$828,093
R01 · FY2010 · HL · contact PI
Comparative Effectiveness of Biologics for Psoriasis$500,000
RC1 · FY2010 · AR · contact PI
The Risk of Myocardial Infarction in Patients with Psoriasis$9,686
R01 · FY2010 · HL · contact PI
The Risk of Myocardial Infarction in Patients with Psoriasis$787,421
R01 · FY2009 · HL · contact PI
Comparative Effectiveness of Biologics for Psoriasis$500,000
RC1 · FY2009 · AR · contact PI
Investigating the Risk of Lymphoma in Psoriasis Patients$132,462
K23 · FY2008 · AR · contact PI
Investigating the Risk of Lymphoma in Psoriasis Patients$132,462
K23 · FY2007 · AR · contact PI
Investigating the Risk of Lymphoma in Psoriasis Patients$132,462
K23 · FY2006 · AR · contact PI
Investigating the Risk of Lymphoma in Psoriasis Patients$132,462
K23 · FY2005 · AR
Investigating the Risk of Lymphoma in Psoriasis Patients$132,462
K23 · FY2004 · AR
Surrogate markers of complete venous ulcer healing$65,395
F32 · FY2002 · AR
Surrogate markers of complete venous ulcer healing$66,351
F32 · FY2001 · AR